In proteasome inhibitor therapy of MM, DDI2 knockout blocks NFE2L1 cleavage and nuclear translocation, which increases the sensitivity of proteasome inhibitor (CFZ)-induced cytotoxicity both in vitro and in vivo [121]. The gene discussed is NFE2L1; the disease is Miyoshi myopathy.